$BPTH
BIO-PATH HOLDINGS, INC.

2024 Q3 Form 10-Q Financial Statement

#000155837024012259 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.165M
YoY Change -2.18%
% of Gross Profit
Research & Development $1.317M $1.873M
YoY Change -42.54% -38.61%
% of Gross Profit
Depreciation & Amortization $28.00K
YoY Change 27.27%
% of Gross Profit
Operating Expenses $2.634M $3.038M
YoY Change -19.6% -28.38%
Operating Profit -$2.634M -$3.038M
YoY Change -19.6% -28.38%
Interest Expense $6.000K
YoY Change -25.0%
% of Operating Profit
Other Income/Expense, Net $519.0K $1.169M
YoY Change 574.03% 14512.5%
Pretax Income -$1.869M
YoY Change -55.86%
Income Tax
% Of Pretax Income
Net Earnings -$2.115M -$1.869M
YoY Change -33.89% -55.86%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70 -$1.16
Diluted Earnings Per Share -$0.70 -$1.16
COMMON SHARES
Basic Shares Outstanding 2.552M 1.656M
Diluted Shares Outstanding 3.017M 1.612M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.006M
YoY Change 16.32%
Cash & Equivalents $562.0K $4.006M
Short-Term Investments
Other Short-Term Assets $1.806M $700.0K
YoY Change 0.33% -59.91%
Inventory
Prepaid Expenses $531.0K $274.0K
Receivables
Other Receivables
Total Short-Term Assets $2.899M $5.019M
YoY Change -39.63% -19.81%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $48.00K
YoY Change -54.35% -57.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $66.00K $99.00K
YoY Change -69.86% -62.64%
TOTAL ASSETS
Total Short-Term Assets $2.899M $5.019M
Total Long-Term Assets $66.00K $99.00K
Total Assets $2.965M $5.118M
YoY Change -40.95% -21.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.036M $800.0K
YoY Change 245.33% 25.39%
Accrued Expenses $2.313M $2.200M
YoY Change 131.3% 225.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.375M $3.010M
YoY Change 148.71% 111.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $817.0K
YoY Change 1385.45%
Total Long-Term Liabilities $817.0K
YoY Change 1385.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.375M $3.010M
Total Long-Term Liabilities $817.0K
Total Liabilities $3.677M $3.827M
YoY Change 47.32% 158.41%
SHAREHOLDERS EQUITY
Retained Earnings -$114.7M -$112.6M
YoY Change 10.09% 11.48%
Common Stock $4.000K $2.000K
YoY Change -63.64% -75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$700.0K $1.300M
YoY Change
Total Liabilities & Shareholders Equity $2.965M $5.118M
YoY Change -40.95% -21.55%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.115M -$1.869M
YoY Change -33.89% -55.86%
Depreciation, Depletion And Amortization $28.00K
YoY Change 27.27%
Cash From Operating Activities -$4.266M
YoY Change 29.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.220M
YoY Change
NET CHANGE
Cash From Operating Activities -4.266M
Cash From Investing Activities
Cash From Financing Activities 7.220M
Net Change In Cash 2.954M
YoY Change -189.87%
FREE CASH FLOW
Cash From Operating Activities -$4.266M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1612000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
398000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1130000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
398000
CY2024Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2024Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2283000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.89
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2283190
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 dei Document Type
DocumentType
10-Q
CY2024Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q2 dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2024Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q2 dei Entity File Number
EntityFileNumber
001-36333
CY2024Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2024Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2024Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2024Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2024Q2 dei City Area Code
CityAreaCode
832
CY2024Q2 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2024Q2 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q2 dei Trading Symbol
TradingSymbol
BPTH
CY2024Q2 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q2 dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2552190
CY2024Q2 us-gaap Cash
Cash
4006000
CY2023Q4 us-gaap Cash
Cash
1052000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
274000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
739000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1358000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
5019000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3042000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1072000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102000
CY2024Q2 us-gaap Assets
Assets
5118000
CY2023Q4 us-gaap Assets
Assets
3220000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
766000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
457000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2189000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1346000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3010000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1906000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
817000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000
CY2024Q2 us-gaap Liabilities
Liabilities
3827000
CY2023Q4 us-gaap Liabilities
Liabilities
2779000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2283000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113922000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108047000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112633000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107607000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1291000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
441000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5118000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3220000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1873000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3051000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4161000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7040000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1165000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1191000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2572000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2494000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3038000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4242000
us-gaap Operating Expenses
OperatingExpenses
6733000
us-gaap Operating Expenses
OperatingExpenses
9534000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3038000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4242000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6733000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9534000
CY2024Q2 bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-1163000
bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-1701000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1169000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1707000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1869000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4234000
us-gaap Net Income Loss
NetIncomeLoss
-5026000
us-gaap Net Income Loss
NetIncomeLoss
-9507000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.89
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1612000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
398000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1130000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
398000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-5026000
us-gaap Profit Loss
ProfitLoss
-9507000
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
311000
us-gaap Share Based Compensation
ShareBasedCompensation
376000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
51000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47000
CY2024Q2 us-gaap Depreciation
Depreciation
28000
us-gaap Depreciation
Depreciation
44000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1701000
CY2024Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-358000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2518000
CY2024Q2 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-619000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
102000
CY2024Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1152000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-263000
CY2024Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-58000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-53000
CY2024Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4266000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6940000
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7220000
CY2024Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7220000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2954000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6940000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1052000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4006000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3444000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9107000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
170000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4234000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5043000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2625000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5644000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
141000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1869000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1291000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14174000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
376000
us-gaap Net Income Loss
NetIncomeLoss
-9507000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5043000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
441000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5565000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
311000
us-gaap Net Income Loss
NetIncomeLoss
-5026000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1291000
CY2024Q2 us-gaap Cash
Cash
4000000.0
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
700000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1400000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
800000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
500000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2200000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1300000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
817000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1300000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
400000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2283190
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
600000
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-012259-index-headers.html Edgar Link pending
0001558370-24-012259-index.html Edgar Link pending
0001558370-24-012259.txt Edgar Link pending
0001558370-24-012259-xbrl.zip Edgar Link pending
bpth-20240630.xsd Edgar Link pending
bpth-20240630x10q.htm Edgar Link pending
bpth-20240630xex31.htm Edgar Link pending
bpth-20240630xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bpth-20240630_def.xml Edgar Link unprocessable
bpth-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bpth-20240630_pre.xml Edgar Link unprocessable
bpth-20240630x10q_htm.xml Edgar Link completed
bpth-20240630_cal.xml Edgar Link unprocessable